Perioperative anesthesia protocol for electroconvulsive therapy — pre-anesthesia screening, induction agent selection, cuffed-limb muscle relaxation, biphasic autonomic monitoring, and post-anesthesia recovery
Every electroconvulsive therapy (ECT) session is a brief general anesthetic delivered to a patient who may have significant cardiac, pulmonary, or metabolic comorbidity. Structured pre-anesthesia assessment — repeated before every session, not just the first — identifies risk before induction, confirms fasting status to prevent aspiration, and reviews the medication list for agents that interfere with seizure induction, most notably benzodiazepines.
ECT produces a predictable, transient hemodynamic stress test: a vagal bradycardic dip at stimulus delivery followed by a sympathetic surge with marked tachycardia and hypertension during the seizure itself. For most patients this is well tolerated, but it is not trivial in patients with:
• Recent myocardial infarction or unstable angina — increased demand ischemia risk during the sympathetic surge • Significant arrhythmia or conduction disease — the vagal bradycardic phase can be exaggerated • Uncontrolled hypertension — baseline BP should be optimized before the course begins • Aneurysm or recent intracranial hemorrhage — transient pressure surges carry rupture risk • Severe pulmonary disease — brief apnea during induction and the seizure itself reduces respiratory reserve
A baseline ECG, review of cardiac history, and — when indicated — cardiology clearance are obtained before the first treatment. Because a course of ECT typically spans 6–12 sessions over several weeks, the assessment is repeated at each visit: vital signs, interval cardiac or pulmonary events, and any new medications are re-checked every time, not only at intake.
Because ECT requires brief general anesthesia with airway instrumentation (bag-mask ventilation, occasionally supraglottic or endotracheal support), standard NPO (nil per os) guidelines apply exactly as for any elective anesthetic:
• Clear liquids: up to 2 hours before • Light meal / non-human milk: up to 6 hours before • Solids / fried or fatty food: up to 8 hours before
Fasting status is confirmed verbally with the patient and documented immediately before each session — this is a routine, mandatory checkpoint given how frequently ECT sessions recur and how easily a single missed confirmation could lead to aspiration during airway management.
The single most consequential medication-review finding in ECT anesthesia is benzodiazepine use. Benzodiazepines are GABA-A receptor agonists that raise the seizure threshold and can shorten or entirely prevent an adequate therapeutic seizure — directly undermining the efficacy of the treatment.
• Ideally, benzodiazepines are minimized or held for 24–48 hours before each session when clinically safe to do so • If a benzodiazepine cannot be safely discontinued (e.g., active alcohol/benzodiazepine withdrawal risk, severe anxiety), the treatment team weighs risk against benefit and may adjust stimulus dosing to compensate • Other anticonvulsant medications (valproate, lamotrigine, high-dose anticholinesterase-interacting drugs) are reviewed for the same reason • Conversely, some medications lower seizure threshold and require caution for a different reason — certain antipsychotics and bupropion, for example — these are noted but not necessarily held, since a lower threshold is not itself dangerous unless seizures become prolonged
Benzodiazepine review is treated as a standing checklist item, not a one-time note: because a full ECT course spans weeks, a benzodiazepine started mid-course for anxiety or sleep can silently blunt seizure adequacy in later sessions if it is not re-screened at every visit.
ECT anesthesia uses a brief-acting intravenous induction agent to produce unconsciousness for the few minutes the procedure requires. The three agents in common use — methohexital, etomidate, and propofol — are pharmacologically similar in their rapid onset and offset, but differ meaningfully in how they affect seizure threshold and seizure duration, which is why agent selection is itself a clinical decision rather than a fixed default.
Methohexital, an ultra-short-acting barbiturate, has long served as the reference induction agent for ECT because its effect on seizure threshold is relatively neutral compared with the alternatives — it neither markedly shortens nor prolongs the induced seizure at standard dosing. It provides rapid, predictable induction and rapid emergence, and decades of clinical experience make its risk profile well characterized. Its main drawbacks are pain on injection and, occasionally, myoclonic movement that can be confused with seizure activity if not distinguished carefully by EEG and cuffed-limb observation.
Etomidate is notable for lowering seizure threshold, which translates clinically into longer and more robust induced seizures. This makes it a common second-line choice when a patient has repeatedly shown short or inadequate seizures under other agents, or when concurrent medications (including benzodiazepines that could not be fully held) are pushing seizure threshold upward.
Trade-offs include a higher incidence of myoclonus and post-treatment nausea, and — with repeated or prolonged exposure — a theoretical concern about adrenocortical suppression, which is not typically clinically significant for the brief, intermittent dosing used in ECT but is part of why etomidate is usually reserved rather than used as first line.
Propofol has anticonvulsant properties: it raises seizure threshold and tends to shorten seizure duration compared with methohexital or etomidate. Its major advantage is hemodynamic smoothness — it blunts the sympathetic surge more than the other agents, produces very rapid, clear-headed emergence, and causes less post-treatment myalgia and nausea. This makes it attractive for patients where cardiovascular stability is the dominant concern (e.g., significant cardiac disease).
The trade-off is direct: propofol's anticonvulsant effect can compromise seizure adequacy, so it is used cautiously — and sometimes avoided — in patients who already tend toward borderline seizure duration.
Agent selection is a continuous balancing act between two competing goals: an adequately robust therapeutic seizure and a hemodynamically tolerable anesthetic. There is no universally "best" agent — the choice is individualized to each patient's seizure history and cardiac risk, and may be changed between sessions within the same course.
A generalized tonic-clonic seizure without muscle relaxation carries a real risk of fractures, dislocations, and soft-tissue injury. Succinylcholine, a rapid-onset, short-duration depolarizing neuromuscular blocker, is dosed to attenuate this motor activity throughout the body — while the cuffed-limb technique deliberately preserves visible motor seizure activity in one isolated limb, giving the clinical team a direct, real-time window onto seizure adequacy.
Succinylcholine is the standard muscle relaxant for ECT because its pharmacokinetic profile matches the procedure almost perfectly: onset within about a minute and spontaneous recovery within roughly 5–10 minutes, requiring no reversal agent. It works by depolarizing the neuromuscular junction and preventing repetitive muscle contraction, which converts what would otherwise be a full-body convulsion into a modified, largely attenuated motor response — dramatically reducing musculoskeletal injury risk while leaving the underlying cerebral seizure activity, and its therapeutic effect, unchanged.
Dosing is titrated: enough to substantially blunt generalized motor activity, but calibrated so that at least one limb can still be observed moving, since complete paralysis would remove the clinician's ability to visually confirm seizure adequacy.
Before succinylcholine is injected, a blood pressure cuff is inflated on one limb (classically an ankle or forearm) to a pressure above systolic blood pressure, occluding arterial flow into that limb. When succinylcholine is then given intravenously, it circulates and paralyzes the rest of the body — but cannot reach the muscles distal to the inflated cuff in meaningful concentration during the brief window of the procedure.
As a result, when the electrical stimulus is delivered and a seizure is induced, the isolated limb continues to display visible tonic-clonic motor activity while the rest of the body remains still and protected. This gives the treatment team a direct visual confirmation of motor seizure activity and duration, used alongside EEG seizure monitoring, without exposing the patient to injury risk from a full-body convulsion.
Succinylcholine carries a small but important list of contraindications and cautions that are screened for during pre-anesthesia assessment:
• Personal or family history of malignant hyperthermia — an absolute contraindication • Pseudocholinesterase deficiency — prolongs paralysis well beyond the expected 5–10 minutes, requiring ventilatory support until recovery • Hyperkalemia risk states (recent major burns, denervation injury, certain neuromuscular diseases) — succinylcholine can trigger dangerous potassium release • History of significant myalgia with prior use — sometimes managed with a small pretreatment dose or an alternative non-depolarizing agent at reduced ECT-appropriate dosing
The cuffed-limb technique is considered, together with EEG, the standard for direct seizure monitoring in ECT: it converts an otherwise invisible (fully paralyzed) seizure into an observable one, without sacrificing the injury protection that muscle relaxation provides.
Electrical stimulation and the seizure it produces trigger a well-characterized, biphasic autonomic cardiovascular response: a brief parasympathetic (vagal) surge causing transient bradycardia at the moment of stimulus, immediately followed by a much larger and longer sympathetic surge causing tachycardia and hypertension for the duration of the seizure and shortly after. Continuous ECG, blood pressure, pulse oximetry, and airway monitoring are mandatory throughout this window.
The electrical stimulus itself triggers a brief, centrally-mediated parasympathetic discharge. Clinically this appears as a transient drop in heart rate — sometimes a brief sinus bradycardia, occasionally asystole of a few seconds in susceptible patients — lasting roughly ten to fifteen seconds around the moment of stimulation, before the second phase takes over.
In patients with significant conduction disease, or where this bradycardic response has been pronounced in prior sessions, anticholinergic pretreatment (e.g., glycopyrrolate) may be used to blunt the vagal phase. This decision is individualized and weighed against the fact that anticholinergics will also tend to accentuate the subsequent tachycardic phase.
As the generalized seizure activity begins, a much larger sympathetic discharge follows: heart rate and blood pressure both rise substantially above baseline, often persisting for the duration of the seizure and for a short period afterward before gradually normalizing. This is the physiologically dominant phase of the cardiovascular response and the one of greatest concern in patients with coronary disease, aneurysm, or uncontrolled hypertension, since it represents a genuine — if brief — increase in myocardial oxygen demand and intracranial/intravascular pressure.
Management options when the surge needs to be blunted include short-acting beta-blockade (e.g., esmolol) or nitrate/antihypertensive pretreatment in selected high-risk patients, always balanced against the possibility of over-blunting and masking a genuinely inadequate cardiovascular response.
Patients are pre-oxygenated before induction and typically ventilated by bag-mask during the brief apneic period that follows induction and muscle relaxation. A bite block is placed before stimulus delivery to protect the teeth and tongue from the jaw-clenching that can occur even with muscle relaxation, since masseter muscles are less completely blocked than large limb muscle groups.
Continuous pulse oximetry confirms adequate oxygenation throughout; capnography is added whenever a supraglottic airway or endotracheal tube is used. Airway support continues through the seizure and into the immediate post-ictal period until spontaneous, adequate ventilation resumes.
The biphasic response is expected and self-limited in the overwhelming majority of treatments — the monitoring requirement exists precisely because a small subset of patients (significant cardiac or cerebrovascular disease) need the surge actively managed rather than simply observed.
Once the seizure ends and the muscle relaxant wears off, the patient enters a recovery phase that is monitored with the same rigor as recovery from any brief general anesthetic — vital signs, airway reflexes, and level of consciousness are tracked until the patient is stable, plus an additional and ECT-specific watch for post-ictal confusion and agitation as the patient reorients.
Recovery monitoring begins the moment the seizure and muscle relaxation resolve. The team confirms return of spontaneous, adequate ventilation; protective airway reflexes (swallow, cough); and hemodynamic stabilization back toward the patient's baseline. Continuous pulse oximetry and intermittent blood pressure and heart rate checks continue until these criteria are clearly met — typically well within the first several minutes after the procedure, given how short-acting all the anesthetic agents used are.
A period of post-ictal confusion — disorientation, grogginess, occasionally agitation — is expected after the induced seizure and is distinct from ordinary anesthetic emergence. It is usually brief, resolving over minutes, but can be more pronounced or prolonged in elderly patients, those with baseline cognitive impairment, or after sessions with longer seizure duration.
Management is primarily supportive: a calm, quiet recovery environment, gentle reorientation, and physical safety measures (side rails, staff presence) to prevent injury during the confused interval. Pharmacologic intervention for agitation is used sparingly and only when the patient poses a safety risk to themselves or staff, since sedating medications can complicate assessment of true recovery.
Before transfer out of the recovery area (or discharge home, for outpatient ECT), the patient must meet standard post-anesthesia discharge criteria — commonly assessed with a scoring tool such as the Aldrete score — covering stable vital signs, adequate oxygenation, return of motor function, and a level of consciousness and orientation consistent with the patient's own baseline.
For outpatient courses in particular, patients are also required to have a responsible adult escort and are advised not to drive, operate machinery, or make significant decisions for the remainder of the day, given the residual post-ictal and anesthetic effects that can persist subtly beyond formal discharge criteria.
Because ECT is delivered as a repeated course rather than a single event, recovery observations from each session (confusion duration, hemodynamic recovery time, any adverse response) feed back into planning the next session — including possible adjustments to induction agent or muscle relaxant dosing discussed in earlier stages.